论文部分内容阅读
目的:探讨通心络胶囊联合阿托伐他汀治疗冠心病心绞痛的疗效及对血浆基质金属蛋白酶9(MMP-9)、内皮素1(ET-1)和超敏C反应蛋白(hs-CRP)表达的影响。方法:选择湖州市第一人民医院2017年9月至2019年9月收治的冠心病心绞痛患者174例，按照随机数字表法分为对照组与观察组各87例。观察组采用通心络胶囊联合阿托伐他汀治疗，对照组采用阿托伐他汀治疗。两组疗程均为12周。比较两组治疗前和治疗12周心绞痛发作次数、心绞痛发作时间、MMP-9、ET-1和hs-CRP水平变化，及治疗疗效和用药期间不良反应情况。结果:观察组治疗12周心绞痛发作次数为(2.17±0.67)次/周，少于对照组的(3.41±0.52)次/周(n t＝13.637，n P<0.05)；观察组治疗12周心绞痛持续时间为(1.72±0.43)min/次，短于对照组的(2.89±0.56)min/次(n t＝14.457，n P<0.05)；观察组治疗12周血浆MMP-9为(236.21±37.49)μg/L、ET-1为(43.57±8.10)ng/L和hs-CRP为(2.64±0.41)mg/L，均低于对照组的(328.39±45.21)μg/L、(58.73±5.46)ng/L和(3.82±0.56)mg/L(n t＝14.693、14.476、15.858，均n P<0.05)；观察组治疗总有效率(91.95%)高于对照组(78.16%)(χn 2＝6.511，n P<0.05)。观察组不良反应发生率(8.05%)低于对照组(20.69%)(χn 2＝5.652，n P<0.05)。n 结论:通心络胶囊联合阿托伐他汀治疗冠心病心绞痛患者疗效明显，可降低血浆MMP-9、ET-1和hs-CRP表达，且无明显不良反应。“,”Objective:To investigate the therapeutic effect of Tongxinluo capsule combined with atorvastatin in the treatment of angina pectoris and its effect on the expression of matrix metalloproteinase-9 (MMP-9), endothelin-1 (ET-1) and high sensitive C-reactive protein (hs-CRP).Methods:From September 2017 to September 2019, 174 patients with coronary heart disease and angina pectoris in the First People's Hospital of Hangzhou were divided into control group and treatment group according to the random digital table method, with 87 cases in each group.The treatment group was treated with Tongxinluo capsule and atorvastatin, while the control group was treated with atorvastatin.The course of treatment in both two groups was 12 weeks.The number of angina pectoris attack, angina pectoris attack time, MMP-9, ET-1 and hs-CRP levels were compared between the two groups before treatment and 12 weeks after treatment.Results:The number of angina attacks in the observation group was (2.17±0.67)times/week, which was lower than that in the control group [(3.41±0.52)times/week] (n t=13.637, n P<0.05). The duration of angina pectoris in the observation group [(1.72±0.43)min/time] was lower than that in the control group [(2.89±0.56)min/time] (n t=14.457, n P<0.05). The plasma MMP-9[(236.21±37.49)μg/L], ET-1[(43.57±8.10)ng/L] and hs-CRP [(2.64±0.41)mg/L] in the observation group were lower than those in the control group [(328.39±45.21) μg/L, (58.73±5.46)ng/L and (3.82±0.56)mg/L] (n t=14.693, 14.476, 15.858, all n P<0.05). The total effective rate of the observation group (91.95%) was higher than that of the control group (78.16%) (χn 2=6.511, n P<0.05). The incidence of adverse reactions in the observation group (8.05%) was lower than that in the control group (20.69%)(χn 2=5.652, n P<0.05).n Conclusion:Tongxinluo capsule combined with atorvastatin is effective in the treatment of angina pectoris of coronary heart disease.It can reduce the levels of MMP-9, ET-1 and hs-CRP in plasma, and has no obvious adverse reactions.